Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Marstacimab - Pfizer

Next Previous
Drug Profile

Marstacimab - Pfizer

Alternative Names: HYMPAVZI; Hympavzi; Marstacimab-hncq - Pfizer; PF-06741086; PF-6741086

Latest Information Update: 02 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antihaemorrhagics; Coagulants; Monoclonal antibodies
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B; Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Haemophilia A; Haemophilia B

Most Recent Events

  • 26 Jun 2025 Efficacy and adverse events data from the phase III BASIS trial in Haemophilia A and B released by Pfizer
  • 13 May 2025 Pfizer initiates enrolment in a Hemophilia A (In Children, In Adolescents, In adults and In elderly, Treatment-experienced) (NCT06703606)
  • 29 Apr 2025 Pfizer completes a phase-III clinical trials in Haemophilia B (In adults, In adolescents, In the elderly) in USA, Bulgaria, Canada, China, Croatia, France, Hong Kong, India, Italy, Japan, South Korea, Mexico, Oman, Russia, Saudi Arabia, Serbia, South Africa, Spain, Taiwan, Turkey and USA (SC) (NCT03938792)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top